The stunning success of Novo Nordisk A/S's semaglutide has filled the coffers of the controlling shareholder of the Danish drugmaker which is dipping into its mountain of cash to acquire contract manufacturer Catalent, Inc for $16.5bn.
Novo Splashes Out Again To Solve Semaglutide Supply Problem
Novo Nordisk is buying three manufacturing facilities for $11bn from Catalent, which has just been acquired by the former's main shareholder Novo Holdings, in its latest bid to meet surging demand for its semaglutide-based diabetes and obesity drugs.
More from Manufacturing
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
J&J followed in the footsteps of Lilly and Merck, which have announced multibillion-dollar investments in US manufacturing since Donald Trump’s inauguration.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.